ORAL ANTICOAGULANTS IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
https://doi.org/10.21518/2307-1109-2017-1-74-83
Abstract
The review discusses the results of using oral anticoagulants to improve the prognosis of patients after exacerbation of coronary artery disease. Based on a review of the available randomized clinical trials, the authors conclude that rivaroxaban at a dose of 2.5 mg twice daily has the best efficacy/safety ratio. Administration of rivaroxaban at the mentioned dose within 1 year after the development of acute coronary syndrome helps to reduce cardiovascular and total mortality and the risk of stent thrombosis.
References
1. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes winthout ST-segment elevation. N Engl J Med, 2001, 345:494-502.
2. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361: 1045-1057.
3. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UKBelgian Study). Eur Heart J, 2010, 31(22): 2755-2764.
4. Lahoud R, Howe M, Krishnan SM et al. Effect of use of combination evidence-based medical therapy after acute coronary syndromes on long-term outcomes. Am J Cardiol, 2012, 109(2): 159-164.
5. Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation, 1994, 90: 61-68.
6. Ardissino D, Merlini PA, Bauer KA et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood, 2003, 102(8): 2731-2735.
7. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med, 2002, 347(13): 969-974.
8. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133(6 Suppl): 160S-198S.
9. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxisafter myocardial infarction: the ESTEEM randomised controlled trial. Lancet, 2003, 362(9386): 789-797.
10. Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phaseII trial. Eur Heart J, 2011, 32(22): 2781-2789.
11. Alexander JH, Becker RC, Bhatt DL et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation, 2009, 119(22): 2877-2885.
12. Hess CN, James S, Lopez RD et al. Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial. J Am Coll Cardiol, 2015, 66(7): 777-787.
13. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet, 2009, 374(9683): 29-38.
14. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med, 2012, 366(1): 9-19.
15. Mega JL, Braunwald E, Murphy SA et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol, 2013, 61(18): 1853-1859.
16. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007, 115(17): 2344-2351.
17. Gibson CM, Chakrabarti AK, Mega J et al. Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol, 2013, 62(4): 286-290.
18. Steg PhG, James SR, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012, 33: 2569-2619.
19. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016, 37: 267-315.
20. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2014, 35(37): 2541-2619.
21. Руда М.Я., Аверков О.В., Голицын С.П. и др. Диагностика и лечение больных острым инфарктом мио-карда с подъемом сегмента ST электрокардиограммы. Российские рекомендации. М., 2014.
Review
For citations:
Perepech N.B. ORAL ANTICOAGULANTS IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME. Aterotromboz = Atherothrombosis. 2017;(1):28-42. (In Russ.) https://doi.org/10.21518/2307-1109-2017-1-74-83
Views:
1147
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 